Leaflet: information for the user
Conoxia 99.5% (v/v) cryogenic medicinal gas
Oxygen
Read the entire leaflet carefully before starting to use this medication, as it contains important information for you.
Contents of the leaflet
Conoxia 99.5% (v/v) cryogenic medicinal gas is an inhalation gas supplied in a liquid state in cryogenic containers at cryogenic temperatures (approx. -183°C).
It contains oxygen, in a concentration of 99.5% v/v or higher.
It does not contain other excipients.
Oxygen is an essential element for the body. Oxygen therapy is indicated in the following cases:
The treatment with oxygen is indicated in the following cases:
Do not use Conoxia 99.5% (v/v) cryogenic medicinal gas
This medication cannot be used at high pressure in cases of untreated pulmonary collapses (untreated pneumothorax). A pulmonary collapse is an accumulation of gas in the thoracic cavity between the two pulmonary membranes.
Tell your doctor if you have had a pulmonary collapse in the past.
Warnings and precautions
Consult your doctor, pharmacist, or nurse before starting to use Conoxia 99.5% (v/v) cryogenic medicinal gas.
You should inform your doctor if you have a chronic pulmonary disease such as bronchitis, emphysema, or asthma, and in severe cases of oxygen deficiency.
No fatty substances (vaseline, ointments, etc.) should be applied to the face, due to the risk of inflammation of this medication (see section 6).
In certain severe cases of oxygen deficiency, after 6 hours of exposure to a concentration of Oxygen of 100%, or after 24 hours of exposure to a concentration of Oxygen higher than 70%, pulmonary or neurological toxicity may occur (see sections 3 and 6). Therefore, high concentrations should be used for as short a time as possible and controlled by analyzing the gases in arterial blood, while measuring the concentration of inhaled Oxygen.
It is advisable to use the lowest effective dose to maintain the arterial partial pressure of Oxygen (PaO2) at 50-60 mmHg (i.e., 5.65-7.96 kPa) and, after 24 hours of exposure, to maintain, as far as possible, an Oxygen concentration below 45%.
Precautions for use
Children
In newborns, especially if they are premature, eye damage (retinal alterations) may occur with certain concentrations of oxygen.
In infants who need a concentration higher than 30%, the arterial partial pressure of Oxygen (PaO2) should be regularly controlled to not exceed 100 mmHg (i.e., 13.3 kPa).
Use of Conoxia 99.5% (v/v) cryogenic medicinal gas with other medications
Tell your doctor or pharmacist if you are using, have recently used, or may need to use any other medication.
The toxicity of Oxygen may be increased by: corticosteroids, some cancer medications, paraquat, sympathomimetics, X-rays, or in cases of hyperthyroidism or deficiency of vitamins C and E or glutathione.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Conoxia 99.5% (v/v) cryogenic medicinal gas has been widely used without any notable effects.
Driving and using machines
There are no data on the effect of Conoxia 99.5% (v/v) cryogenic medicinal gas on driving and using machines.
Follow the administration instructions of this medication exactly as indicated by your doctor. In case of doubt, consult your doctor again.
Your doctor will determine the correct dose of Conoxia 99.5% (v/v) cryogenic medicinal gas and administer it using a system suitable for your needs, ensuring the supply of the correct amount of Oxygen.
If you think the effect of Conoxia 99.5% (v/v) cryogenic medicinal gas is too strong or too weak, tell your doctor.
If you use more Conoxia 99.5% (v/v) cryogenic medicinal gas than you should
In case of overdose, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount inhaled.
In case of overdose, the concentration of inhaled Oxygen should be decreased, and symptomatic treatment is recommended.
Like all medications, Conoxia 99.5% (v/v) cryogenic medicinal gas may cause side effects, although not everyone will experience them.
In chronic respiratory failure, in particular, there is a possibility of apnea. Inhalation of high concentrations of Oxygen may cause small collapses in the lung.
Administration of Oxygen at high pressures may cause injuries to the inner ear (which may pose a risk of rupture of the eardrum), the nasal sinuses, and the lungs (which may pose a risk of pneumothorax).
Seizures have been reported after administration of Oxygen with a concentration of 100% for more than 6 hours, particularly with administration at high pressure.
Pulmonary injuries may occur after administration of Oxygen concentrations higher than 80%.
In newborns, especially if they are premature, exposed to high concentrations of Oxygen (FiO2 > 40%; PaO2 higher than 80 mmHg, i.e., 10.64 kPa), or for a prolonged period (more than 10 days at a concentration FiO2 > 30%), there is a risk of retinopathies, which appear between 3 and 6 weeks after treatment, and may experience regression or cause retinal detachment, or even permanent blindness.
Patients undergoing high-pressure oxygen therapy in chambers may experience claustrophobia.
If you experience side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date shown on the label after {CAD}. The expiration date is the last day of the month indicated.
All regulations regarding the handling of pressure vessels must be followed. With regard to storage and transportation, the following must be taken into account:
Storage of cryogenic containers:
Liquid containers must be stored dry and clean in a covered area, protected from atmospheric agents and wind, and dedicated to the storage of medicinal gases. They must also be protected from heat sources or ignition, temperatures equal to or higher than 50°C, and combustible materials.
Precautions must be taken to avoid shocks, blows, or falls.
Empty and full containers must be stored separately.
Storage of containers at home:
Containers must be installed in a location that allows protection from the risks of blows and falls, heat sources or ignition, temperatures equal to or higher than 50°C, combustible materials, and weather conditions.
Excessive storage should be avoided.
Transportation of containers:
Containers must be transported with the help of suitable material to protect them from the risk of blows or falls.
During transportation in vehicles, containers must be well secured. Permanent ventilation of the vehicle is mandatory, and smoking is strictly prohibited.
Composition of Conoxia 99.5% (v/v) cryogenic medicinal gas
Appearance of the product and package contents
Conoxia 99.5% (v/v) cryogenic medicinal gas is an inhalation gas.
It is supplied in liquid form in cryogenic containers of different capacities or in tanks.
The different presentations are:
Not all pack sizes may be marketed.
Marketing authorization holder:
Linde GAS ESPAÑA, S.A.U.
C/ Camino de Liria, s/n,
post office box 25,
Puzol, 46530 Valencia, Spain
Manufacturer:
LINDE GAS ESPAÑA, S.A.U.
P.I. Bañuelos, C/ Haití, 1; Alcalá de Henares (Madrid) – 28806 – Spain.
or
LINDE GAS ESPAÑA, S.A.U.
P.I. Can Pí de Vilaroch., Avd. Antonio Gaudí, 151; Rubí (Barcelona) – 08191- Spain.
or
LINDE GAS ESPAÑA, S.A.U.
C/ Camino de Liria, s/n, Puzol – 46530, Valencia, Spain.
or
LINDE GAS ESPAÑA, S.A.U.
Políono Industrial Ciudad de Transporte P-27.1 A 27.4, Jerez de la Frontera, 11407 Cádiz, Spain.
or
OXIGENO DE SAGUNTO, S.L.
Parque Industrial de Sagunto, Esq NE, Parcela AMS, C/ Acería s/n
46520 Puerto de Sagunto (Valencia), Spain
or
LINDE PORTUGAL, LDA
Loteamento Vilar do Senhor, Unidade J
Vila Nova da Telha, Portugal
or
Linde GAS ESPAÑA , S.A.U.
C/Hamburgo, 16, Pol El Bierzo
24400 Ponferrada, Spain
or
MESSER IBERICA DE GASES, S.A.
Polígono Industrial El Morell s/n, El Morell, Tarragona 43760, Spain.
or
Linde GAS ESPAÑA , S.A.U.
C/ Pico Ocejón, 40; Torija 19190, Guadalajara, Spain.
Date of the last revision of this leaflet:June 2009.
Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es.
--------------------------------------------------------------------------------------------------------------------This information is intended only for healthcare professionals:
Instructions for use/handling
Do not smoke.
Do not approach a flame.
Do not grease.
In particular:
To avoid any incidents, it is necessary to strictly follow the following instructions: